(function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); skip to primary navigationskip to content

Professor Roger Alistair Barker

Professor Roger Alistair Barker

Office Phone: (3)31184


Roger A. Barker is the Professor of Clinical Neuroscience and Honorary Consultant in Neurology at the University of Cambridge and at Addenbrooke’s Hospital. He trained at Oxford and London and undertook his clinical and research training in Cambridge as well as the National Hospital for Neurology in London.

His research looks at neurodegenerative disorders of the nervous system in particular Parkinson’s disease and Huntington’s disease. He combines basic research looking at novel therapies (including cell transplants and gene therapies) to treat these conditions with clinically based work on defining the natural history and heterogeneity of both Huntington’s disease and Parkinson’s disease. He is the co-ordinator of the FP7 Transeuro project looking at fetal cell grafting in patients with early PD and a founding member of the GFORCE=PD stem cell initiative.

Departments and Institutes

Clinical Neurosciences:
Professor of Clinical Neuroscience

Research Interests

Parkinson's and Huntington's disease

Key Publications


  1. Breen DP, Rowe JB, Barker RA (2011) Role of brain imaging in early parkinsonism. BMJ. 342:d638
  2. Kehagia AA, Barker RA, Robbins TW (2012). Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis. Neurodegener Dis. 11:79-92
  3. T.Foltynie, T.W.Robbins, C.Brayne, R.A.Barker (2004). Cognitive impairments are common among a population cohort of newly diagnosed PD patients - the CamPaIGN study. Brain 127:550-60.
  4. Cheesman AL; Barker RA; Lewis SJG; Owen AM; Robbins TW; Brooks DJ (2005). Lateralisation of striatal function: Evidence from 18F-dopa PET in Parkinson’s disease. JNNP 76:1204-10.
  5. Williams-Gray CH, Robbins TW, Brayne C, Barker RA (2007). The evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787-1798.
  6. Williams-Gray CH, Hampshire A, Owen AM*, Barker RA* (2007)  COMT val158met genotype influences frontoparietal activity during planning in patients with Parkinson’s disease. J.Neurosci. 27:4832-4838. [* joint senior last authors].
  7. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJG, Brown J, ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA*, Sawcer SJ * (2007) Tau and alpha-synuclein in susceptibility to, and Dementia in, Parkinson’s disease. Ann.Neurol. 62: 145-153. [* joint senior authors].
  8. Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason SJ, Polkey CE, Clough C, Brooks DJ, Barker RA, Piccini P (2008). Long term clinical and PET outcome of foetal striatal transplantation in Huntington’s disease. J Neurol Neurosurg Psychiatry. 79:948-951.
  9. O’Keefe G, Tyers P, Aarsland D, Dalley J, Caldwell MA*, Barker RA* (2009) Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc.Natl.Acad Sci. 106:8754-9 [*joint senior authors].
  10. Clelland CD, Choi M, Romberg C, Clemenson GD Jr, Fragniere A, Tyers P, Jessberger S, Saksida LM, Barker RA*, Gage FH*, Bussey TJ (2009). A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science 325;210-213. [*joint senior authors]. 
  11. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009). The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 132:2958-69. 
  12. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Hum Brain Mapp. 32:258-70.
  13. Wu K, O’Keefe, Politis M, O’Keeffe GC, Robbins TW, Bose SK, Brooks DJ, Piccini P, Barker RA (2012). The catechol-O-methyltransferase Val 158Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson’s Disease; a PET study. Brain. 135:2449-57.
  14. Winder-Rhodes* SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, Duran R, Mencacci NE, Sawcer SJ, Barker RA (2013).  Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136:392-399. 
  15. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA (2013) The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 84:1258-64. 
  16. Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Westervelt HJ, Johnson HJ, Aylward EH, Zhang Y, Bockholt HJ, Barker RA; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Prediction of manifest Huntington’s Disease with clinical and imaging measures; a prospective observational study (2014). Lancet Neurol. 13: 1193-201. 
  17. Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ; the ICICLE-PD study group, Barker RA (2014). Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain. 137: 2743-58. 
  18. Kuan WL, Kasis A, Yuan Y, Mason SL, Lazar AS, Barker RA, Goncalves J. (2014). Modelling the natural history of Huntington’s disease progression. J Neurol Neurosurg Psychiatry.
  19. Winder-Rhodes SE, Hampshire A, Rowe JB, Peele JE, Robbins TW, Owen AM, Barker RA. (2015). Association between MAPT haplotype and memory function in patients with Parkinson’s disease and healthy aging individuals. Neurobiol. Aging. 36: 1519-28.
  20. Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini MG, Cicchetti F, Barker RA. (2015). The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain 138: 1907-18.